Compare McKesson Corporation (MCK) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Shell PLC — how do they compare? McKesson Corporation trades at $878 (market cap $105.14B), while Shell PLC trades at $90.39 (market cap $250.44B). The key difference: Shell PLC is far larger — about 2.4× McKesson Corporation's market cap, and Shell PLC pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| MCK | SHEL | |
|---|---|---|
Market Cap | $105.14B | $250.44B |
Sector | Health | Energy |
52-Week High | $995.69 | $94.15 |
52-Week Low | $659.01 | $70.31 |
Enterprise Value | $111.67B | $292.14B |
Dividend Yield | 0.42% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
SHEL trades at $90.12, up 0.19% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beating estimates. The stock shows attractive valuation metrics with a P/E of 10.01 and P/S of 0.88, supported by a 14.35% ROE and 8.76% net income margin. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments, such as selling its European renewables unit to TotalEnergies.
Outlook remains positive due to discounted valuation, rising cash flow, and analyst consensus favoring buys with a $103.60 price target. Key risks include commodity price volatility, regulatory pressures, and execution challenges in energy transitions. The stock offers value with upside potential but requires monitoring of oil market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
